Latest News

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

As global markets navigate the final month of 2025, investors are closely watching for potential interest rate cuts from central banks, while grappling with mixed economic signals such as declining manufacturing activity and resilient service sector growth. Amid these conditions, identifying undervalued stocks—those trading below their intrinsic worth—can offer opportunities for investors seeking value in a fluctuating market landscape.

As global markets navigate a complex landscape marked by hopes for interest rate cuts and mixed economic signals, investors are increasingly focused on strategies that can provide steady returns amid uncertainty. In this environment, dividend stocks stand out as a compelling option, offering the potential for regular income while participating in market growth.

Let's talk about the popular ASSA ABLOY AB (publ) ( STO:ASSA B ). The company's shares saw a double-digit share price...

When you see that almost half of the companies in the Logistics industry in India have price-to-sales ratios (or "P/S...

Janux Therapeutics (JANX) just dropped updated interim data from its Phase 1 JANX007 trial in advanced prostate cancer, and the mixed reaction is exactly what is driving the stock debate right now. See our latest analysis for Janux Therapeutics. That mixed read on JANX007 landed in a stock that has already been under pressure, with a roughly 51 percent 7 day share price return and a steep year to date slide, but a still positive 3 year total shareholder return suggesting earlier optimism has...

Distribution Solutions Group (DSGR) has turned heads by hiring seasoned deal maker Sean Dwyer as Senior Vice President, Head of M&A and Strategy, a move that sharpens the company’s playbook for acquisition driven growth. See our latest analysis for Distribution Solutions Group. That strategic hire lands at an interesting moment, with the share price at $27.46 and a recent 1 month share price return of 5.01%, yet a much weaker year to date share price return of negative 18.54% and a 1 year...

New Fortress Energy (NFE) has quietly bounced, with shares up around 12% in a day and almost 20% over the past week, despite a steep slide this year. Let us unpack what might be changing. See our latest analysis for New Fortress Energy. That bounce comes after a brutal stretch, with the latest 1 year total shareholder return still deep in the red. As a result, this sharp 7 day share price move looks more like early momentum than a full trend change. If this rebound has you rethinking your...

Eisai and Biogen recently presented new long-term data at the CTAD 2025 conference showing that Leqembi (lecanemab) treatment, including a subcutaneous autoinjector formulation, may substantially delay progression from mild cognitive impairment to more advanced Alzheimer’s disease while maintaining a safety profile consistent with earlier trials. The findings that earlier and continued Leqembi use could translate into several additional years before patients reach moderate Alzheimer’s stage,...

First Merchants (FRME) has quietly outperformed many regional peers over the past month, even as its stock remains below year highs, giving investors a fresh chance to revisit its long term growth story. See our latest analysis for First Merchants. Zooming out, the recent 1 month share price return of 3.64 percent still leaves First Merchants below its recent highs, while a 1 year total shareholder return of negative 9.49 percent shows longer term momentum has been softer even as fundamentals...

Amylyx Pharmaceuticals recently presented early safety and tolerability data from its Phase 1 LUMINA trial of AMX0114 in ALS at the 36th International Symposium on ALS/MND in San Diego, reporting no treatment-related serious adverse events in the first cohort and planning to begin enrollment of the second cohort in Canada and the US. The presentation at a major ALS/MND forum highlights Amylyx’s attempts to advance its ALS pipeline, potentially reinforcing confidence in AMX0114’s early...

National Energy Services Reunited (NasdaqCM:NESR) has suddenly jumped onto more investors radar after GeoSphere Capital Management boosted its stake and the company clinched a multi year fracturing contract tied to Saudi Arabias Jafurah gas field. See our latest analysis for National Energy Services Reunited. That backdrop helps explain why the share price has climbed to $14.87, with a 20.11 percent 1 month share price return and a striking 70.14 percent 1 year total shareholder return...

In November 2025, SharkNinja, Inc. launched the Shark EveryMess, a portable three-in-one system in the U.S. that wet vacuums, dry vacuums, and deep cleans stains using ultra-powerful suction and StainForce stain-fighting technology, targeting fast, whole-home cleanup for busy households. The product’s combination of multi-surface wet and dry cleaning, stain removal, self-cleaning features, and AnyBag Technology highlights SharkNinja’s push to deepen its edge in high-convenience, premium home...

Trevi Therapeutics (TRVI) has quietly turned into one of the market’s bigger biotech gainers this year, with the stock up sharply over the past 3 months as traders reassess its pipeline potential. See our latest analysis for Trevi Therapeutics. Zooming out, that surge fits into a powerful run, with Trevi’s year to date share price return above 200 percent and a one year total shareholder return above 400 percent, suggesting momentum is still building as investors re-rate its IPF cough...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

As most Gulf markets experience gains buoyed by expectations of a U.S. Federal Reserve interest rate cut, investors are keeping a keen eye on the Middle East's economic landscape, where rising oil prices and geopolitical factors also play significant roles. In this environment, identifying promising stocks involves looking for companies that can leverage these macroeconomic conditions to drive growth and resilience in their respective sectors.

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Key Insights Significantly high institutional ownership implies Exxaro Resources' stock price is sensitive to their...

Last week, you might have seen that AJ Bell plc ( LON:AJB ) released its full-year result to the market. The early...

With a price-to-earnings (or "P/E") ratio of 40.5x Jupiter Wagons Limited ( NSE:JWL ) may be sending very bearish...

In recent months, Procore Technologies announced three major developments: an AWS Marketplace and Amazon Bedrock AI integration, a CEO transition to Dr. Ajei Gopal, and the rollout of its Groundbreak AI suite for construction workflows. Together, these moves highlight Procore’s push to embed AI deeper into construction management, potentially broadening its platform’s role across the global building ecosystem. Next, we’ll examine how the new AWS partnership could reshape Procore’s existing...

The latest buzz around Smart Sand (SND) stems from its shares pushing to fresh multi year highs, as sustained demand for northern white fracking sand and related logistics keeps investors focused on the company. See our latest analysis for Smart Sand. The surge to a $3.89 share price caps an impressive run, with an 86.12% 1 month share price return and a 168.58% 3 year total shareholder return signalling that momentum is firmly building rather than fading. If this proppant rally has you...

Toro (TORO) just put real cash on the table, declaring a one time 1.75 dollar special dividend that investors can take in cash or shares, and it is large enough to trigger due bill trading. See our latest analysis for Toro. The special dividend reflects a sharp shift in sentiment, with Toro’s share price return up triple digits over the past quarter and its 1 year total shareholder return above 250 percent. This suggests strong, momentum driven optimism around future cash generation. If you...

Exelixis (EXEL) has quietly rewarded patient shareholders, with the stock up around 31% year to date and roughly 24% over the past year, outpacing many mid cap biotech peers. See our latest analysis for Exelixis. The latest leg higher has been driven less by headline grabbing news and more by steadily improving sentiment, with an 8.7% 1 month share price return feeding into a powerful three year total shareholder return above 180% that signals momentum is still very much on Exelixis' side. If...